JP2024511453A5 - - Google Patents
Info
- Publication number
- JP2024511453A5 JP2024511453A5 JP2023558500A JP2023558500A JP2024511453A5 JP 2024511453 A5 JP2024511453 A5 JP 2024511453A5 JP 2023558500 A JP2023558500 A JP 2023558500A JP 2023558500 A JP2023558500 A JP 2023558500A JP 2024511453 A5 JP2024511453 A5 JP 2024511453A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2104040.7 | 2021-03-23 | ||
| GBGB2104040.7A GB202104040D0 (en) | 2021-03-23 | 2021-03-23 | New compounds |
| GBGB2113583.5A GB202113583D0 (en) | 2021-09-23 | 2021-09-23 | New compounds |
| GB2113583.5 | 2021-09-23 | ||
| PCT/GB2022/050725 WO2022200785A1 (en) | 2021-03-23 | 2022-03-23 | Selective angiotensin ii receptor ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024511453A JP2024511453A (ja) | 2024-03-13 |
| JP2024511453A5 true JP2024511453A5 (https=) | 2025-03-31 |
| JPWO2022200785A5 JPWO2022200785A5 (https=) | 2025-03-31 |
Family
ID=81254760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023558500A Pending JP2024511453A (ja) | 2021-03-23 | 2022-03-23 | 選択的アンジオテンシンｉｉ受容体リガンド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240182461A1 (https=) |
| EP (1) | EP4313953A1 (https=) |
| JP (1) | JP2024511453A (https=) |
| CA (1) | CA3212900A1 (https=) |
| WO (1) | WO2022200785A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE20230600A3 (en) | 2022-12-22 | 2025-09-24 | Vicore Pharma Ab | A method of treating a patient diagnosed with an interstitial lung disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126342A (en) * | 1990-10-01 | 1992-06-30 | Merck & Co., Inc. | Imidazole angiotensin ii antagonists incorporating acidic functional groups |
| US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| KR100938817B1 (ko) * | 2001-05-31 | 2010-01-26 | 바이코어 파마 아베 | 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물 |
| CA2449150C (en) | 2001-05-31 | 2011-07-12 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| WO2003064414A1 (en) * | 2002-01-29 | 2003-08-07 | Vicore Pharma Ab. | Tricyclic compounds useful as angiotensin ii agonists |
| WO2004046141A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| US8835471B2 (en) | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| BR112017012337A2 (pt) | 2014-12-12 | 2018-02-27 | Vicore Pharma Ab | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. |
| WO2016107879A2 (en) | 2014-12-30 | 2016-07-07 | Vicore Pharma Ab | New use of angiotensin ii receptor agonists |
| CN107405406A (zh) | 2015-03-02 | 2017-11-28 | 维科尔药物公司 | 用于治疗肺纤维化的血管紧张素ii受体激动剂 |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
| GB201913603D0 (en) * | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
| KR20230004501A (ko) * | 2020-03-19 | 2023-01-06 | 바이코어 파마 아베 | 안지오텐신 ⅱ와 관련된 질병, 장애, 또는 병태의 치료 및/또는 예방에 유용한 신규 화합물 |
| GB202004094D0 (en) * | 2020-03-20 | 2020-05-06 | Vicore Pharma Ab | New compounds and uses |
| GB202013721D0 (en) * | 2020-09-01 | 2020-10-14 | Vicore Pharma Ab | New compounds |
-
2022
- 2022-03-23 EP EP22714509.1A patent/EP4313953A1/en active Pending
- 2022-03-23 CA CA3212900A patent/CA3212900A1/en active Pending
- 2022-03-23 JP JP2023558500A patent/JP2024511453A/ja active Pending
- 2022-03-23 WO PCT/GB2022/050725 patent/WO2022200785A1/en not_active Ceased
- 2022-03-23 US US18/283,489 patent/US20240182461A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025003637A1 (es) | Anticuerpos anti-tgf-beta 1 latente y métodos de uso. | |
| JP2024511453A5 (https=) | ||
| CL2025004057A1 (es) | Intermedio inhibidor de dpp1, y método de preparación para el mismo y uso del mismo en medicamentos. | |
| CL2025003851A1 (es) | Métodos de tratamiento de alzheimer utilizando un anticuerpo anti-abeta protofibril. | |
| CL2025003023A1 (es) | Motor hidráulico | |
| BR102023012440A2 (https=) | ||
| BR102023009641A2 (https=) | ||
| BR102023008688A2 (https=) | ||
| BY13172U (https=) | ||
| BY13165U (https=) | ||
| CN307048387S (https=) | ||
| CN307047273S (https=) | ||
| CN307046641S (https=) | ||
| CN307045344S (https=) | ||
| CN307049363S (https=) | ||
| CN307045115S (https=) | ||
| CN307045059S (https=) | ||
| CN307044364S (https=) | ||
| BY23969C1 (https=) | ||
| BY23968C1 (https=) | ||
| BY23965C1 (https=) | ||
| BY13176U (https=) | ||
| BY13175U (https=) | ||
| BY13174U (https=) | ||
| CN307049493S (https=) |